Stock Events

Stock Events

Eledon Pharmaceuticals 

€2.50
40
+€0.02+0.81% 09:48 Today

Statistics

Day High
2.5
Day Low
2.48
52W High
3.72
52W Low
1.19
Volume
-
Avg. Volume
-
Mkt Cap
203.15M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q1 2026
Q2 2026
Next
-0.28
-0.23
-0.19
-0.14
Expected EPS
-0.15655639999999998
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-39.3MNet Income

Analyst Ratings

9.11Average Price Target
The highest estimate is 9.11.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2TK.STU. It's not an investment recommendation.
SoFi Technologies
5
SOFI
Plug Power
5
PLUG
Archer Aviation
5
ACHR
NVIDIA
4
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurodegenerative diseases, directly competing with Eledon's focus on neurological conditions.
Regenxbio
RGNX
Mkt Cap637.69M
REGENXBIO is involved in gene therapy for neurodegenerative diseases, overlapping with Eledon's therapeutic areas.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, competing in the same space as Eledon's focus on treatments for autoimmune diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals works on RNAi therapeutics for genetic diseases, some of which are in direct competition with Eledon's focus areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals engages in creating treatments for serious diseases, including cystic fibrosis, which could overlap with Eledon's target disease areas.
Novartis
NVS
Mkt Cap292.35B
Novartis offers a broad range of healthcare solutions, including treatments for neurological conditions that compete with Eledon's portfolio.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including treatments for neurological and autoimmune diseases, competing with Eledon's research areas.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, known for antiviral drugs, also explores treatments in areas that could compete with Eledon's focus on autoimmune diseases.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a diverse portfolio, including drugs for neurological and autoimmune disorders, directly competing with Eledon Pharmaceuticals.

About

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
Show more...
CEO
David-Alexandre C. Gros
Employees
33
Country
United States
ISIN
US28617K1016
WKN
000A2QL00

Listings

STU
DE
2TK.STU
MU
DE
2TK.MU
F
DE
2TK.F
XNAS
US
ELDN

0 Comments

Share your thoughts

FAQ

What is Eledon Pharmaceuticals stock price today?▼
The current price of 2TK.STU is €2.50 EUR — it has increased by +0.81% in the past 24 hours. Watch Eledon Pharmaceuticals stock price performance more closely on the chart.
What is Eledon Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Eledon Pharmaceuticals stocks are traded under the ticker 2TK.STU.
Is Eledon Pharmaceuticals stock price growing?▼
2TK.STU stock has fallen by -8.09% compared to the previous week, the month change is a -16.67% fall, over the last year Eledon Pharmaceuticals has showed a +14.68% increase.
What is Eledon Pharmaceuticals market cap?▼
Today Eledon Pharmaceuticals has the market capitalization of 203.15M
When is the next Eledon Pharmaceuticals earnings date?▼
Eledon Pharmaceuticals is going to release the next earnings report on November 18, 2026.
What were Eledon Pharmaceuticals earnings last quarter?▼
2TK.STU earnings for the last quarter are -0.23 EUR per share, whereas the estimation was -0.14 EUR resulting in a -70.89% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Eledon Pharmaceuticals revenue for the last year?▼
Eledon Pharmaceuticals revenue for the last year amounts to 0 EUR.
What is Eledon Pharmaceuticals net income for the last year?▼
2TK.STU net income for the last year is -39.3M EUR.
How many employees does Eledon Pharmaceuticals have?▼
As of September 04, 2026, the company has 33 employees.
In which sector is Eledon Pharmaceuticals located?▼
Eledon Pharmaceuticals operates in the Health & Wellness sector.
When did Eledon Pharmaceuticals complete a stock split?▼
The last stock split for Eledon Pharmaceuticals was on October 05, 2020 with a ratio of 1:18.
Where is Eledon Pharmaceuticals headquartered?▼
Eledon Pharmaceuticals is headquartered in IRVINE, United States.